Xencor, Inc. (NASDAQ:XNCR – Get Free Report) has been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $34.78.
Several research analysts recently weighed in on the stock. BMO Capital Markets restated an “outperform” rating and set a $32.00 price target on shares of Xencor in a report on Tuesday, August 6th. Royal Bank of Canada boosted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Wedbush restated an “outperform” rating and set a $34.00 price target on shares of Xencor in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. cut their price target on shares of Xencor from $30.00 to $27.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st.
Read Our Latest Stock Analysis on Xencor
Institutional Trading of Xencor
Xencor Price Performance
Shares of NASDAQ XNCR opened at $21.16 on Friday. The stock has a market capitalization of $1.30 billion, a P/E ratio of -9.66 and a beta of 0.67. The company has a 50-day moving average price of $19.51 and a 200-day moving average price of $20.11. Xencor has a 1 year low of $15.31 and a 1 year high of $26.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.
Xencor (NASDAQ:XNCR – Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The business had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm’s quarterly revenue was down 62.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.37) earnings per share. On average, equities research analysts forecast that Xencor will post -4.11 EPS for the current fiscal year.
About Xencor
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
- Five stocks we like better than Xencor
- Bank Stocks – Best Bank Stocks to Invest In
- Texas Roadhouse Stock Steering for New Highs This Year
- Energy and Oil Stocks Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is a SEC Filing?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.